Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Company Overview - Avadel is a growing biotech company that has transformed itself over the past five years [3] - The company is currently in its ninth quarter of launching LUMRYZ, a once-at-bedtime oxybate for treating narcolepsy [4] Product Performance - LUMRYZ is designed for patients suffering from excessive daytime sleepiness (EDS) and cataplexy, applicable to both adults and pediatrics [4] - The company has over 3,100 patients currently using LUMRYZ, indicating a growing business and increasing number of prescribers [4] Financial Status - Avadel has achieved a cash flow positive state as a commercial stage organization [5] - The company is in the latter stages of a pivotal Phase III trial aimed at expanding indications for idiopathic hypersomnia [5]